目的 調(diào)查2018—2019年復(fù)旦大學(xué)附屬婦產(chǎn)科醫(yī)院紫杉醇類藥品的使用情況，為婦科惡性腫瘤患者治療合理用藥提供相關(guān)數(shù)據(jù)資料。方法 回顧性分析復(fù)旦大學(xué)附屬婦產(chǎn)科醫(yī)院2018—2019年醫(yī)囑中含紫杉醇類藥品的使用情況，對藥品的使用量、銷售金額、患者年齡、臨床診斷、藥品的用法用量、用藥療程等進(jìn)行整理與分析。結(jié)果 共收集含紫杉醇類藥品醫(yī)囑12 398條，涉及7種紫杉醇類藥品，兩年年總使用量68 170瓶，用量前3名分別是國產(chǎn)多西他賽注射液22 633瓶，構(gòu)成比為33.20%；國產(chǎn)注射用紫杉醇脂質(zhì)體20 273瓶，構(gòu)成比為29.74%，國產(chǎn)紫杉醇注射液13 430瓶，構(gòu)成比為19.70%。銷售金額前3名的分別是國產(chǎn)注射用紫杉醇脂質(zhì)體1 625.59萬元，構(gòu)成比為46.93%，進(jìn)口紫杉醇注射液587.99萬元，構(gòu)成比為16.98%，進(jìn)口注射用紫杉醇（白蛋白結(jié)合型）577.70萬元，構(gòu)成比為16.68%。使用紫杉醇類藥品最多的年齡段是59～60歲，構(gòu)成比為34.88%。臨床診斷數(shù)的前3位分別宮頸癌908例，構(gòu)成比為53.57%，卵巢癌697例，構(gòu)成比為41.12%，乳腺癌564例，構(gòu)成比為33.27%。紫杉醇脂質(zhì)體和紫杉醇注射液的最常使用量為210 mg，進(jìn)口多西他賽注射液的最常使用量為100 mg，國產(chǎn)多西他賽注射液的最常使用量為120 mg，進(jìn)口注射用紫杉醇（白蛋白結(jié)合型）的最常使用量為150 mg。紫杉醇類藥品療程數(shù)分布1～39次，其中療程小于10次的人數(shù)構(gòu)成比為96.74%。結(jié)論 2018—2019年復(fù)旦大學(xué)附屬婦產(chǎn)科醫(yī)院紫杉醇類藥品的使用合理，但還需要更多地關(guān)注不良反應(yīng)發(fā)生等相關(guān)問題，確?；颊甙踩⒂行?、經(jīng)濟(jì)用藥，并進(jìn)一步結(jié)合臨床真實(shí)數(shù)據(jù)的分析，規(guī)范紫杉醇類藥品領(lǐng)域評價原則，建立較為完整的評估系統(tǒng)。

Objective To analyze the clinical use of paclitaxel drugs in Obstetrics and Gynecology Hospital Affiliated to Fudan University from 2018 to 2019, and to provide reference for the rational treatment of patients with gynecological tumors. Methods The uses of paclitaxel drugs in Obstetrics and Gynecology Hospital Affiliated to Fudan University from 2018 to 2019 were analyzed retrospectively, including usages, sales, ages of patients, clinical diagnoses, dosage and course of treatment. Results A total of 12 398 medical orders containing paclitaxel drugs were collected, involving 7 kinds of paclitaxel drugs. The total amount used in the two years was 68 170 bottles. The drugs with top three dosages were Domestic Docetaxel Injection, 22 633 bottles, accounting for 33.20%, Domestic Paclitaxel Liposome for injection, 20 273 bottles, accounting for 29.74%, and Domestic Paclitaxel Injection, 13 430 bottles, accounting for 19.70%. The drugs with top three sales amount were Domestic Paclitaxel Liposome for injection with an amount of RMB 16.25 million, accounting for 46.93%, Imported Paclitaxel Injection with RMB 5.88 million, accounting for 16.98%, and Imported Paclitaxel injection (albumin-binding type) with RMB 5.78 million, accounting for 16.68%. The age group with the most paclitaxel drugs using was people aged 59 — 60 years, accounting for 34.88%. The top three clinical diagnoses were cervical cancer with 908 patients, accounting for 53.57%, ovarian cancer with 697 patients, accounting for 41.12%, and breast cancer with 564 patients, accounting for 33.27%. The most commonly dosage of Paclitaxel Liposome and Paclitaxel Injection was 210 mg, while 100 mg for Imported Docetaxel Injection, 120 mg for Domestic Docetaxel Injection, and 150 mg for Imported Paclitaxel Injection (albumin-binding type). The treatment courses of paclitaxel drugs are distributed from 1 to 39 times, and 96.74% of the patients have less than 10 treatment courses. Conclusion From 2018 to 2019, the use of paclitaxel drugs in Obstetrics and Gynecology Hospital Affiliated to Fudan University is reasonable, but some issues such as adverse reactions need to be concerned. The safety, effectiveness, and economical efficiency for patients should be ensured. Furthermore, the clinical real data should be analyzed and a complete evaluation system for clinical use of paclitaxel drugs should be established.

R969.3

上海市臨床藥學(xué)重點(diǎn)?？平ㄔO(shè)項(xiàng)目（AB83110002017005）